

Supplementary Table 4: Baseline characteristics the subset of participants (N=58) included in the analysis for neutralizing antibodies by infectious SARS-CoV-2 neutralisation test (VNA).

	PHH-1V	BNT162b2	Total	Confidence Interval	p-value
Number of subjects, n (%)	34 (6.6)	24 (9.5)	58 (7.6)		
Age, years					
All age groups, <i>median (range)</i>	42.5 (22 – 64)	54 (23 – 70)	48 (22 – 70)	9.04 [1.62, 16.46]	0.0182
18-65, n (%)	34 (100.0)	20 (83.3)	54 (93.1)		
≥ 65, n (%)	0 (0.0)	4 (16.7)	4 (6.9)	∞ (1.37, ∞) [§]	0.0250
Sex					
Female, n (%)	23 (67.6)	16 (66.7)	39 (67.2)		
Male, n (%)	11 (32.4)	8 (33.3)	19 (32.8)	1.04 [0.31, 3.20] [§]	1.0000
Race					
White, n (%)	34 (100.0)	24 (100.0)	58 (100.0)		
Asian, n (%)	0 (0.0)	0 (0.0)	0 (0.0)		
American Indian or Alaska native, n (%)	0 (0.0)	0 (0.0)	0 (0.0)		
Other, n (%)	0 (0.0)	0 (0.0)	0 (0.0)		1.000 [†]
Ethnicity					
Hispanic or Latino, n (%)	24 (70.6)	16 (66.7)	40 (69.0)		
Not Hispanic or Latino, n (%)	10 (29.4)	8 (33.3)	18 (31.0)	1.20 [0.34, 3.84] [§]	0.7799
BMI, median (range)	24.0 (18.8 – 39.8)	24.2 (18.7 – 32.0)	24.1 (18.7 – 39.8)	0.87 [-1.28, 3.02]	0.4219
Time between second dose and booster, median (range)	293 (189 – 337)	291 (189 – 317)	292 (189 – 337)		0.2882 [‡]
Time boost to extraction, median (range)	14 (13 – 20)	14 (13 – 15)	14 (13 – 20)		0.2047 [‡]

Confidence intervals estimated using T-tests are shown as mean difference [95% confidence interval]. Where specified (§), confidence intervals estimated using Fisher's Exact test are shown as odds ratio [95% confidence interval].

[†] Data analysed by means of Fisher's Exact test.

[‡] Data analysed by means of Anderson-Darling's test.